Table III.

Multivariate analysis to predict progression-free survival in patients with metastatic and unresectable urothelial carcinoma who received pembrolizumab.

Factor	Hazard ratio	P-value
Age (continuous)	1.00 (0.98–1.03)	0.72
Sex (female)	1.81 (1.07–3.05)	0.03
Hemoglobin (<10 g/dl)	1.33 (0.83–2.14)	0.24
ECOG-PS (≥1)	1.25 (0.78–2.00)	0.35
Time from prior chemotherapy (<3 months)	1.61 (1.00–2.60)	0.05
Liver metastasis (presence)	1.54 (0.89–2.67)	0.13
CRP responder	0.46 (0.26–0.79)	0.01
CRP flare-responder high BL	0.46 (0.21–1.04)	0.06
CRP flare-responder low BL	0.31 (0.12–0.80)	0.02

ECOG, Eastern Cooperative Oncology Group; PS, performance Status; CRP, C-reactive protein; BL, baseline.